EP Patent

EP2435583A1 — miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY

Assigned to Universita degli Studi di Roma La Sapienza · Expires 2012-04-04 · 14y expired

What this patent protects

The invention relates to the therapy of Duchenne Muscular Dystrophy (DMD) by means of modulating the amount of a specific miRNA (miR-31).

USPTO Abstract

The invention relates to the therapy of Duchenne Muscular Dystrophy (DMD) by means of modulating the amount of a specific miRNA (miR-31).

Drugs covered by this patent

Patent Metadata

Patent number
EP2435583A1
Jurisdiction
EP
Classification
—
Expires
2012-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Universita degli Studi di Roma La Sapienza
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.